At Thermo Fisher Scientific we pride ourselves on providing adaptive, scientifically focused, comprehensive development services at every stage of your drug development journey. Each of our oral solid dose (OSD) drug development facilities have the capabilities and expertise to run early phase drug development programs. To further support and enhance OSD early development services to clients, we have two standalone facilities which are centers of excellence for OSD early phase development situated in North America and Europe. The multidisciplinary onsite teams are experienced in the following:
Our one-of-kind, computational modelling tool, Quadrant 2® rapidly accelerates early formulation development challenges for poorly soluble API’s. Quadrant 2® uses the API properties and the intended clinical dose to predict the solubility enhancement technology, formulation components and composition most likely to increase solubility and PK exposure prior to conducting any screening experiments. In as little as 2 weeks from initial consultation, you will be provided with a comprehensive report and consultation meeting with a senior scientist that outlines a proposed pathway forward for your product development. Both time and cost are therefore significantly reduced in contrast to conducting traditional trial and error experimentation approaches.
In as little as 14 weeks from API receipt, the Quick-to-Clinic™ program delivers Phase 1 drug product manufactured, labelled, packaged and delivered to the clinic. This one-of-a-kind program delivers: